Philip Hempleman increased its stake in Marrone Bio Innovations Inc (MBII) by 181.08% based on its latest 2018Q1 regulatory filing with the SEC. Ardsley Advisory Partners bought 6.67M shares as the company’s stock rose 56.14% while stock markets declined. The hedge fund run by Philip Hempleman held 10.35M shares of the basic industries company at the end of 2018Q1, valued at $12.73M, up from 3.68 million at the end of the previous reported quarter. Ardsley Advisory Partners who had been investing in Marrone Bio Innovations Inc for a number of months, seems to be bullish on the $195.53 million market cap company. The stock decreased 2.75% or $0.05 during the last trading session, reaching $1.77. About 301,705 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 48.33% since June 17, 2017 and is uptrending. It has outperformed by 35.76% the S&P500. Some Historical MBII News: 07/05/2018 – Marrone Bio Innovations Names Kevin Hammill Chief Comml Officer; 30/04/2018 – Grandevo® CG and Venerate® CG Approved for Use on Cannabis by the Colorado, Washington and Nevada Departments of Agriculture; 18/04/2018 – Marrone Bio Innovations to Use Proceeds for General Corporate Purposes; 15/03/2018 – MARRONE BIO INNOVATIONS REPORTS ZEQUANOX DISTRIBUTION PACT; 15/05/2018 – Waddell & Reed Financial Inc. Exits Marrone Bio Innovations; 15/03/2018 – MARRONE BIO INNOVATIONS – SIGNS DISTRIBUTION AGREEMENT WITH SOLENIS TO PROVIDE ZEQUANOX MOLLUSCICIDE TREATMENT PROGRAMS FOR WATER SYSTEMS IN U.S., CANADA; 25/04/2018 – Marrone Bio Innovations and Lidorr Chemicals Ltd. Sign Distribution Agreement in Israel; 24/05/2018 – Marrone Bio Innovations Expands Sales Team and Establishes New Sales Territory; 16/04/2018 – Marrone: 2016, 2017 Financials Modified to Add Paragraph Indicating Substantial Doubt About Company’s Ability to Continue as Going Concern; 16/04/2018 – Regalia® CG Biofungicide Cleared for Use on Cannabis by the Colorado, Oregon, Washington and Nevada Departments of Agriculture
Jnba Financial Advisors increased its stake in Cardinal Health Inc (CAH) by 37.63% based on its latest 2018Q1 regulatory filing with the SEC. Jnba Financial Advisors bought 700 shares as the company’s stock declined 25.69% with the market. The institutional investor held 2,560 shares of the health care company at the end of 2018Q1, valued at $2.56M, up from 1,860 at the end of the previous reported quarter. Jnba Financial Advisors who had been investing in Cardinal Health Inc for a number of months, seems to be bullish on the $17.01B market cap company. The stock increased 0.24% or $0.13 during the last trading session, reaching $54.75. About 5.36 million shares traded or 65.99% up from the average. Cardinal Health, Inc. (NYSE:CAH) has declined 28.59% since June 17, 2017 and is downtrending. It has underperformed by 41.16% the S&P500. Some Historical CAH News: 23/04/2018 – DJ Cardinal Health Inc, Inst Holders, 1Q 2018 (CAH); 07/03/2018 – U.S. judge says opioid settlement roadblocks may prompt trials; 03/05/2018 – Cardinal Health 3Q Adj EPS $1.39; 03/04/2018 – Cardinal Health Inc. CDS Tightens 10 Bps, Most in 3 Years; 03/05/2018 – Cardinal Health Cuts FY18 View To Adj EPS $4.85-Adj EPS $4.95; 20/03/2018 – Cardinal Health Highlights Commitment To Gender Equity As Part Of Women’s History Month Celebrations; 15/05/2018 – U.S. state lawsuits against Purdue Pharma over opioid epidemic mount; 03/04/2018 – Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2018 on May 3; 03/05/2018 – CARDINAL HEALTH INC CAH.N ON CONF CALL SAYS THAT OPERATING COSTS AND INVENTORY RESERVES CONTINUE TO BE CHALLENGES IN CORDIS UNIT; 03/05/2018 – Cardinal Health CDS Widens 13 Bps, Most in 5 Years
Among 4 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marrone Bio Innovations had 9 analyst reports since August 11, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Wednesday, March 21 by Jefferies. Piper Jaffray maintained it with “Hold” rating and $2.0 target in Monday, August 14 report. The stock of Marrone Bio Innovations, Inc. (NASDAQ:MBII) has “Hold” rating given on Tuesday, April 3 by Jefferies. The firm has “Buy” rating by Zacks given on Tuesday, August 11. Piper Jaffray maintained Marrone Bio Innovations, Inc. (NASDAQ:MBII) on Friday, September 15 with “Hold” rating. The stock of Marrone Bio Innovations, Inc. (NASDAQ:MBII) has “Buy” rating given on Tuesday, August 15 by H.C. Wainwright. The firm has “Buy” rating by Rodman & Renshaw given on Wednesday, March 16. The stock of Marrone Bio Innovations, Inc. (NASDAQ:MBII) earned “Hold” rating by Jefferies on Thursday, February 8. The rating was maintained by Piper Jaffray on Friday, July 21 with “Hold”.
Investors sentiment increased to 5.5 in 2018 Q1. Its up 4.93, from 0.57 in 2017Q4. It increased, as 1 investors sold MBII shares while 1 reduced holdings. 6 funds opened positions while 5 raised stakes. 78.12 million shares or 565.72% more from 11.74 million shares in 2017Q4 were reported. Bankshares Of America De reported 10,102 shares. 12,428 were reported by Bluecrest Capital Limited. 24.71 million were accumulated by Waddell & Reed. Morgan Stanley has 480 shares. Carroll Finance accumulated 0% or 2,000 shares. State Street has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Ardsley Advisory Prtn reported 10.35M shares. 77,806 are owned by Blackrock Incorporated. Raymond James Svcs Inc has 11,061 shares. Guggenheim Ltd Limited Liability Company reported 17,851 shares or 0% of all its holdings. Vanguard Group Inc has invested 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Planning Advsr Ltd Limited Liability Company holds 33,079 shares or 0.02% of its portfolio. Primecap Co Ca reported 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). The United Kingdom-based Barclays Public Ltd Limited Liability Company has invested 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Northern Corp holds 31,936 shares or 0% of its portfolio.
Since February 5, 2018, it had 1 buying transaction, and 0 insider sales for $5.00 million activity.
Ardsley Advisory Partners, which manages about $862.45M and $667.25 million US Long portfolio, decreased its stake in Macerich Co (NYSE:MAC) by 189,500 shares to 9,000 shares, valued at $504,000 in 2018Q1, according to the filing. It also reduced its holding in Ishares Tr (IBB) by 4,000 shares in the quarter, leaving it with 13,500 shares, and cut its stake in I D Systems Inc (NASDAQ:IDSY).
More important recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Globenewswire.com which released: “Marrone Bio Innovations, Inc. to Present at 8th Annual LD Micro Invitational Investor Conference in Los Angeles” on May 25, 2018, also Investorideas.com published article titled: “Investor Ideas #Potcasts: #Cannabis News and Stocks on the Move; (CSE: $BE.C), (TSXV:$RLV.V), (NASDAQ: $MBII …”, Nasdaq.com published: “Marrone Bio Innovations’ Amplitudeâ„¢ Biofungicide is Available for This Growing Season’s Fight Against White Mold” on June 12, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) was released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Edge Higher; Navistar Profit Tops Expectations” with publication date: June 05, 2018.
Jnba Financial Advisors, which manages about $564.64 million and $8.99B US Long portfolio, decreased its stake in Wisdomtree Tr (DEM) by 370 shares to 24,931 shares, valued at $24.93M in 2018Q1, according to the filing. It also reduced its holding in Ishares Tr (IJR) by 13,024 shares in the quarter, leaving it with 180,803 shares, and cut its stake in Ishares Tr (SHY).
Since January 22, 2018, it had 0 buys, and 3 sales for $3.82 million activity. 28,532 shares valued at $1.89 million were sold by MORRISON PATRICIA on Wednesday, February 14. Giacomin Jon L sold $549,924 worth of stock.
More news for Cardinal Health, Inc. (NYSE:CAH) were recently published by: Streetinsider.com, which released: “Cardinal Health (CAH) Says FDA Advisory Committee Votes in Favor of its INCRAFT AAA Stent Graft System for …” on June 13, 2018. Seekingalpha.com‘s article titled: “Cardinal Health: At Least 25% Upside” and published on June 12, 2018 is yet another important article.